What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.
CHICAGO, Aug. 5, 2024 /PRNewswire/ — The global Veterinary Surgical Procedures Market is expected to grow from USD 48.3 billion in 2024 to USD 67.8 billion by 2029, at a CAGR of 7.0%. The global veterinary surgical procedures market is experiencing significant transformation due to…
Any American looking to evacuate from Lebanon or Israel should contact Project DYNAMO immediately through its registration page. This mission is completely donor-funded and is being offered as a free service to the Americans being evacuated.
Founded by military veterans in 2021, Project DYNAMO has rescued more than 7,000 Americans from conflict zones around the world, including Afghanistan, Ukraine, Haiti, and Israel. After Hamas terrorists attacked Israel on October 7, 2023, Project DYNAMO leapt into action and successfully and safely evacuated more than 300 Americans back to the United States.
The organization’s decision to extend Operation Galilee Wind to include Lebanon is a direct response to the rapidly escalating instability that poses an imminent threat to American citizens.
“The situation in Israel and Lebanon is deteriorating by the hour, and we have mobilized an excellent and experienced team of military veterans to evacuate Americans at no cost,” said Mario Duarte, President and CEO of Project DYNAMO. “We are moving with urgency to extract U.S. citizens from these volatile regions. Our highly skilled team is fully prepared to navigate the challenges ahead and ensure that no American who wishes to leave is left behind.”
The U.S. State Department’s urgent advisory for Americans to leave Lebanon highlights the gravity of this threat. This critical development has necessitated a swift and robust response from Project DYNAMO, which is now mobilizing its resources to evacuate Americans from both Israel and Lebanon. The organization is coordinating extensively with local contacts, international partners, and government agencies to orchestrate safe passages for those trapped in these high-risk zones.
As this expanded mission gets underway, Project DYNAMO is also asking for public support. Financial contributions are critical to sustaining these life-saving operations. To aid in Project DYNAMO’s mission and ensure that Americans can get home safely, donate here.
“This is a moment of crisis, and we need the public’s help to save lives,” Duarte added. “Every donation directly contributes to our ability to evacuate more Americans from these dangerous situations. We are calling on everyone to stand with us in this urgent mission.”
Project DYNAMO strongly encourages American citizens in Israel and Lebanon who require assistance to contact them immediately.
About Project Dynamo CEO Mario Duarte
Mario Duarte is an internationally recognized intelligence officer with more than 20 years of experience in intelligence, national security, consulting, and strategic initiatives worldwide. Mr. Duarte was instrumental in the decision to move the Guatemalan embassy in Israel from Tel Aviv to Jerusalem, as has been involved with several multiagency and multinational counterterrorist operations in the United States.
Mr. Duarte is also a seasoned expert in humanitarian and emergency evacuation missions. As a Risk and Security Manager for the Houston Airport Authority, Mr. Duarte helped coordinate all airlift evacuations during Hurricane Katrina, which devastated New Orleans in 2005. His commitment to the safety of Americans at home and abroad has made him a critical contributor and leader of Project DYNAMO’s rescue efforts since 2021.
Mario Duarte, President and CEO of Project DYNAMO, is available for interviews. For media inquiries about Operation Galilee Winds and the American evacuation from Lebanon, please contact Caroline Nesbit at [email protected].
For more information about Project DYNAMO, to donate, or to request assistance, please visit http://www.projectdynamo.org.
ABOUT PROJECT DYNAMO
Project DYNAMO is a veteran-led, nonprofit organization dedicated to rescuing American citizens trapped in conflict zones and hostile environments around the world. Founded by U.S. military veterans, the organization has successfully conducted numerous high-risk evacuation missions, often under extreme and dangerous conditions. They operate in “The Grey Space,” which refers to areas where the U.S. government lacks access or presence. Project DYNAMO operates with the belief that no American should be left behind, regardless of their circumstances.
Media Contact
Caroline Nesbiti, Project DYNAMO, (954) 379-2115, [email protected], www.projectdynamo.org
SOURCE Project DYNAMO
Though JAK inhibition has been shown to be effective in GVHD treatment, this trial addressed whether JAK inhibitors have a role in GVHD prophylaxis (prevention). To find ways of preventing acute GVHD, investigators have looked toward the potential of JAK2 inhibitors — drugs that can “turn off” JAK2, a gene that promotes inflammation and contributes to the development of GVHD. The investigational anti-inflammatory drug pacritinib is a JAK2 inhibitor. The JAK1/2 inhibitor ruxolitinib (brand name Jakafi) is indicated for the treatment of refractory GVHD.
The new publication reports findings from a collaborative team of investigators from Roswell Park, the University of Minnesota’s Masonic Cancer Center and Moffit Cancer Center in Florida. The team conducted a phase 2 clinical trial to determine whether adding the Janus kinase 2 (JAK2) inhibitor pacritinib (brand name Vonjo) to the anti-inflammatory drugs sirolimus (brand name Rapamunel) and tacrolimus (brand name Prograf) could prevent acute GVHD in patients who have undergone alloHSCT.
“JAK inhibitors are active in treating GVHD that does not respond to steroids,” explains Dr. Betts. “But the question over the past 10 years has been whether JAK inhibition could prevent GVHD.”
He and his colleagues found the answer in the phase 2 results of a phase 1/2 clinical trial (NCT02891603) that enrolled patients who underwent alloHCT for the treatment of hematological malignancies or myeloproliferative neoplasms — conditions in which the body produces too much of a specific type of blood cell. Twenty-eight patients in the phase 2 study were treated at the University of Minnesota and Moffitt Cancer Center with a regimen of pacritinib/sirolimus/tacrolimus (PAC/SIR/TAC), a combination that the phase 1 study had determined to be safe.
Patients received pacritinib on the day of transplant (Day 0) and for the following 70 days. Sirolimus, an mTOR inhibitor, was administered the day prior to transplant and then daily for at least one year. Tacrolimus, a calcineurin inhibitor, was given three days before transplant and continued for at least 50 days.
The biologic endpoint of the trial was successful, in that PAC/SIR/TAC reduced JAK2 activity in donor T cells, as well as the development of Th1/Th17 cells, thought to be implicated in GVHD onset. Despite achieving this immunologic effect, the incidence of grade 2-4 acute GVHD was very similar to what had been achieved in the past with the use of SIR/TAC alone (46% vs. 43%), demonstrating that adding pacritinib to the regimen did not improve prevention of GVHD.
“We show that JAK inhibition with pacritinib does what we expect immunologically,” says Dr. Betts. “It suppresses JAK2/STAT3 activation and Th1/Th17 cells. However, less-selective approaches like the use of cyclophosphamide after transplantation appear to afford deeper and more durable immune tolerance.”
“This work highlights critical biologic differences between GVHD treatment and GVHD prevention,” he notes. “While our phase 2 trial shows that JAK inhibition with the sirolimus/tacrolimus regimen does not actually prevent GVHD after all, we are eager to see how this combination performs in treating chronic GVHD.”
From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email [email protected].
Media Contact
Ann E Deck-Miller, Roswell Park Comprehensive Cancer Center, 7168458593, [email protected], roswellpark.org
SOURCE Roswell Park Comprehensive Cancer Center
He has been a proponent of carotid artery stenting since the mid-1990s and contributed to research efforts to develop the first embolic protection device. Dr. Ravish Sachar, Contego Medical’s CEO and Founder, stated, “Dr. Silver is a visionary in the cardiovascular space. He has been deeply involved in the treatment of carotid and peripheral vascular disease for many years, and his experience and dedication to advancing medical research prepared him to make a significant impact here. He is uniquely suited for the role of Contego’s CMO, and we are very excited and honored that he will be joining Contego full-time.”
Over the past decade, Dr. Silver’s research focused on deep vein thrombosis (DVT) and pulmonary embolism. He served as the national principal investigator (PI) for the FLAME study, the largest prospective study of interventional treatment in high-risk pulmonary embolism and co-principal investigator of CLEAR DVT, an international study on acute deep venous thrombosis management.
Dr. Silver’s collaboration with Contego Medical dates back to the company’s inception. He served on the company’s board in the early days. “Joining Contego brings my career full circle, and I am energized to join the team at this important time in the company’s trajectory,” he said.
About Contego Medical
Contego Medical, Inc. is the leader in developing state-of-the-art solutions that transform complex cases into simplified procedures. The company’s portfolio of integrated, multi-functional products is designed to improve patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease. More than 3,000 patients have been treated with Contego Medical products to date.
The patented Neuroguard IEP System is currently limited by Federal U.S. law to investigational use only in the PERFORMANCE II study (NCT04201132). The Neuroguard IEP Direct System is currently limited by Federal U.S. law to investigational use only in the PERFORMANCE III study (NCT05845710).
Paladin, Neuroguard IEP, Vanguard IEP, Excipio, Integrated Embolic Protection, and FlexRing are trademarks or registered trademarks of Contego Medical.
Media Contact
Julie Dye, Contego Medical, 1 5125637261, [email protected]
SOURCE Contego Medical
Fertilitywise offers a one-stop solution to empower fertility patients with a library of content that summarizes the science and research of fertility treatments for patients. Membership to the platform also includes a professionally moderated private community, allowing patients to have a safe space to ensure peer-support with others going through a similar journey. Currently, Fertilitywise memberships cost $19.99/month.
“It was a natural choice to partner with Fairfax EggBank, understanding their extensive selection process of egg donors and how they work with their clinics to ensure labs are working with the highest quality methodology. At Fertilitywise, where we focus on summarizing the scientific outcomes for patients, it was a great fit,” Maryanna Basic, Fertilitywise founder stated.
“Fairfax EggBank is delighted to partner with Fertilitywise, allowing us to further extend our commitment to supporting individuals on their fertility journey,” said Sam Marple, MS, Co-President at Fairfax EggBank. “As a trusted provider of frozen donor eggs, we are thrilled to offer our patients access to extended, accurate information and a robust network of resources, empowering them with the tools they need to make informed decisions.”
About Fertilitywise
Fertilitywise is a one-stop, evidence-based resource supporting fertility patients in their journey to pregnancy. Fertilitywise articles are professionally researched and reviewed by leaders in the industry, including reproductive endocrinologists, urologists, embryologists, and genetic counselors. It was founded by Maryanna Basic who, frustrated by a lack of science-backed, accessible information throughout her own fertility journey, decided to create the resource she wished she had. Visit our website at www.fertilitywise.com to learn how we can help support you in your fertility journey.
About Fairfax EggBank
Fairfax EggBank, the trusted choice for frozen donor eggs, provides a diverse selection of pre-screened, FDA-compliant donors to help recipients build their families. Our Donor Database showcases one of the largest repositories for frozen donor eggs in the United States. Our commitment to donor quality and service excellence makes us a premier, yet cost effective, solution for donor egg recipients. Fairfax EggBank benefits from our in-house experts with over 30 years of experience in safe and successful reproductive tissue banking. Visit http://www.fairfaxeggbank.com to learn more.
Media Contact
Christine Joyce, Fertilitywise, 1 6317591512, [email protected], www.fertilitywise.com
SOURCE Fertilitywise
“Patrick’s proven track record of working with early-stage companies to launch new products through a hybrid sales force, his experience working with pathology and pulmonology customers, and his deep understanding of the cancer diagnostic marketplace, make him perfectly suited to direct the launch of our ROSE PrepTM system,” said ASP Health Executive Vice President and Chief Commercial Officer Hari Subramanian, PhD, MBA. “Patrick will build a sales team composed of direct representatives and channel partners, enabling our system to provide enhanced patient care in the field of oncology.”
“I know this market indication very well and believe there is a significant unmet need that the ROSE Prep™ system will be able to address immediately in the diagnostic space. The scalability of our platform will allow us to meet future market needs, including utilizing machine learning to streamline diagnosis. I am thrilled to have the opportunity to apply my nearly 20 years of experience in medical devices, capital equipment, and diagnostics to lead the US market with our commercialization strategy.”
About ASP Health
ASP Health is a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis. ASP Health partners with Planet Innovation, a world-class company known for creating breakthrough products and commercially successful businesses. Its expertise in the research, design, engineering, manufacture, and marketing of new products is accelerating our product development and commercialization efforts. For more information, please visit asp-health.com.
ROSE is a laboratory test that must be performed in accordance with the mandates of CLIA. The scope of practice for a ROSE service is dependent on the needs of the individual health care environment and best determined by the physicians and health care providers in each unique practice setting. The ASP Device may only be used with the General-Purpose Reagents that are recommended for use with the device. Other reagents can be used after they are independently validated by the users of the ASP Device. Sites are responsible to follow the most current version of the CLIA regulations Part 493.
Media Contact
Hari Subramanian, ASP Health Inc., 1 (425) 241-7385, [email protected], asp-health.com
SOURCE ASP Health Inc.
FASTer Way Hydration utilizes premium, unprocessed mineral sources like Celtic Sea Salt and rare Spanish Cave Red Salt. Unlike sports drinks overloaded with sodium, sugars and processed additives, this formula strikes the ideal sodium-to-potassium ratio for optimal hydration delivery at the cellular level without bloating or imbalances.
But that’s just the start. FASTer Way Hydration incorporates the first-of-its-kind probiotic strain Bacillus subtilis AB22. This unique living probiotic not only promotes gut health and immunity, but has the remarkable ability to boost mineral absorption from plant-based foods by breaking down indigestible fiber. The result is maximized nutrient and electrolyte uptake.
The cutting-edge formula is then supercharged with powerful components like methylated B12 and choline for clean energy and brain focus, plus apple cider vinegar for its renowned health properties.
“We see FASTer Way Hydration as the ultimate way to energize your body, nourish your cells, and optimize nutrition from your diet,” explains Tress. “It’s so much more than basic hydration – it’s complete rehydration with synergistic health and performance benefits.”
FASTer Way Hydration is available in Berry and Lemon Lime flavors at a price point of $59.99 for a box of 30 individual packets that dissolve seamlessly into any drink. It is now available for purchase at fasterwaytofatloss.com.
Media Contact
RICHELLE HOENES, FASTer Way to Fat Loss, 1 9415440961, [email protected], FASTer Way to Fat Loss
SOURCE FASTer Way to Fat Loss
The American Med Spa Association (AmSpa) reached out to several of its members to help patients understand what they should expect when researching and receiving non-surgical medical aesthetic treatments.
CHICAGO, Aug. 5, 2024 /PRNewswire-PRWeb/ — Medical spas are experiencing a popularity boom with the industry topping $1.4 billion just in the United States, according to the American Med Spa Association’s 2024 State of the Industry Report. But like any highly lucrative business, not every medical spa practice is created equal and patients need to be more savvy than ever to recognize the signs of a practitioner that will put their safety first. As more and more celebrity attention is drawn to procedures like neuromodulators, filler, microneedling, laser skin resurfacing and more it’s important to understand how to recognize providers and practices doing things the right way.
To help consumers navigate a sea of med spa options, AmSpa – the nation’s leading resource in medical aesthetic legal compliance – asked several industry experts to outline a safe med spa experience. The association polled practitioners from across the country on what to expect from the time a patient is researching a treatment all the way through post-treatment care.
Read here to see what they said.
Interviewees include:
Medical spas are medical practices first and the expectations of these trained clinicians for safe and professional practices are a good measure for anyone looking into how to protect their well-being while undergoing these procedures.
The questions they were asked include:
The vast majority of med spa procedures performed today are safe, but it’s important for consumers to put themselves in the hands of trained, licensed and professional providers. AmSpa supports med spa practices that prioritize legal compliance and patient safety, and guides new med spa owners and providers in how to practice responsibly.
Learn more about AmSpa here.
About the American Med Spa Association (AmSpa)
The American Med Spa Association (AmSpa) provides business, legal and clinical training and resources to medical spas and aesthetic practices throughout the country. AmSpa’s events—including Medical Spa Boot Camps, Academy for Injection Anatomy trainings and Medical Spa Show—provide business and legal best-practices to anyone entering the medical spa space or looking to improve their existing practice. AmSpa Members receive access to legal summaries of laws governing medical spas in their state, discounts, a robust and growing webinar library, and many other benefits. For more information visit http://www.americanmedspa.org, call 312-981-0993, or email [email protected].
Media Contact
Karen Spinelli, American Med Spa Association, 872-246-0300, [email protected], www.americanmedspa.org
SOURCE American Med Spa Association
“Our mission at Shuly Wigs is not just to provide wigs but to restore confidence and bring joy to those who need it most,” said Shuly Amsel, CEO and founder of Shuly Wigs. “Seeing the smile on Anaya’s face when she tried on her new wig was truly priceless. We are honored to be part of her journey and support her in any way we can.”
Josh Aryeh, founder of Smiles Through Cars.org, added, “Collaborations like this are what make our work so rewarding. We are grateful to Shuly Wigs and Adriana Rosie (@nonjewishnanny) for their generosity and dedication to making a positive impact on the lives of children like Anaya. Anaya’s story has touched the hearts of many, and her strength and resilience are an inspiration to us all. We hope this donation not only brings her joy but also raises awareness about the challenges faced by children with cancer and the importance of community support.”
Shuly Wigs is a premier provider of high-quality wigs, dedicated to helping individuals regain their confidence and feel beautiful. With a wide range of styles and custom options, we are committed to meeting the unique needs of each customer. For more information, visit our website at http://www.shulywigs.com or reach out to Brenda at [email protected]. Follow us on Instagram @shulywigs.
Smiles Through Cars.org is a nonprofit organization focused on supporting children with cancer. Through various programs and initiatives, we strive to make a positive impact on their lives and fulfill their dreams. For more information, visit http://www.smilesthroughcars.org.
Media Contact
Shuly Amsel, Shuly Wigs, (718) 851-7778, [email protected], https://shulywigs.com/
SOURCE Shuly Wigs
2024 Class of the Academy:
Glenn Dranoff, MD – Dana-Farber Cancer Institute
Tom Gajewski, MD, PhD – University of Chicago
Ira Mellman, PhD – Genentech
Antoni Ribas, MD, PhD – University of California Los Angeles
Jedd Wolchok, MD, PhD, FAACR, FASCO – Weill Cornell Medicine
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy
SITC solicits nominations and inducts a new class of FAIO on an annual basis. The next call for nominations will be in the spring of 2025.
The Academy of Immuno-Oncology was established by SITC to honor individuals who have launched the field of cancer immunotherapy into the breakthrough cancer treatment it is today, bringing together the brightest minds in the field in order to inspire the next generation of immuno-oncologists.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, Facebook, Instagram and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected], sitcancer.org
SOURCE Society for Immunotherapy of Cancer
